Can BPC-157 Cause Anxiety, Depression or Anhedonia? What the Reports and the Research Show

Where do the reports of anxiety and low mood come from?

From users. One journal has now carried them into print.

In March 2026 a perspective paper in the International Journal of Molecular Sciences summarized the safety picture for BPC-157 and did something unusual. It carried the community reports into the literature. Its authors, writing in the International Journal of Molecular Sciences, said that "anecdotal evidence from the use of BPC-157 has raised concerns" and that "anonymous online user narratives reported injection site swelling and pain, anxiety, heart palpitations, weakness, depression, loss of appetite, fatigue, insomnia, joint pain, drowsiness, and anhedonia."¹

That sentence is the only place in peer-reviewed writing where these specific symptoms are named alongside BPC-157. What it is, and what it is not, decides how much it can carry.

Yuan and colleagues attached their own warning. That paper states that "it is important to recognize that these data are unconfirmed and ought to be treated cautiously, placed low in the evidence hierarchy."¹ They offered a reason the complaints might appear that has nothing to do with the molecule, noting it is "worth considering how these complaints may manifest due to the unregulated production and variable dosing of BPC-157, amongst other causes."¹

So a journal reprinting a symptom list is not a journal finding an effect. No count sits behind that list. No denominator. No assessment of whether the compound caused anything. The passage cites a single reference, numbered 25 in the paper, and the reference list on the page we could read runs out before it, so we cannot tell you what it points at.

This matters more than it looks. Once a symptom list appears in a journal, other writing cites the journal instead of the forum. Nothing new backs it. Only the venue has changed. That list is the same kind of material as a thread, and its authors say so.

Is there any human study of BPC-157 and mood?

No. Not one, on any nervous-system or psychiatric question.

A review in Pharmaceutics in May 2026 put it in a single line: "No human CNS data exist for BPC-157 in any neurological indication."⁴ The same review described the total human record as data that "derive from fewer than 30 subjects across three uncontrolled pilot studies."⁴

Those three studies are small and none of them looked at mood. One was a chart review of 12 people with knee pain. One was a pilot in 12 people with interstitial cystitis. One gave an intravenous infusion to two healthy people.¹ All three share a first author and a journal, so they are not independent checks on each other.

There was a Phase 1 safety trial. That trial, NCT02637284, enrolled healthy volunteers in 2015 and never released its results. The Pharmaceutics review states the trial "was terminated without publication of results."⁴ The FDA's own evaluation notes its estimated enrollment of 42 subjects and says plainly: "There are no results posted."²

A decade on, the one study designed to describe what BPC-157 does to healthy people has never reported.

What has the FDA actually recorded?

Three reports, none of them psychiatric. FDA said that is not enough to conclude anything.

BPC-157 went before the FDA's Pharmacy Compounding Advisory Committee on July 23 and 24, 2026. The briefing document prepared for that meeting is the most thorough official review of the compound that exists, and it is public.²

FDA's Office of Surveillance and Epidemiology "conducted a search of the FAERS database for reports of adverse events (AEs) for BPC-157 through December 4, 2025." The result: "The search retrieved three reports." All three "were associated with injectable BPC-157."²

Report	What was described
1	Nine days of redness and swelling at the injection site, in someone also using injectable compounded thymosin
2	Shortness of breath that led to an emergency room visit
3	Diffuse hyperpigmentation and gingival darkening after a week on a product containing BPC-157 and TB500

Read at source from the FDA briefing document. None of the three is a mood or psychiatric event.²

Two of the three involved a second peptide at the same time. The FDA flagged that as the reason it could not attribute anything. On the third report it wrote that the events "were likely due to the drug product considering that the AEs occurred upon rechallenge; however, because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs."²

The agency's conclusion on safety was blunt. "There is insufficient clinical safety information to characterize the safety profile of BPC-157 (free base) and BPC-157 acetate."²

Why does the public database show more reports than the FDA found?

Anyone can query the same adverse event system themselves through the openFDA interface. Doing that on October 19, 2026 returns 18 reports mentioning BPC-157, not three, and among the reaction terms are one report each of anxiety, depression, obsessive-compulsive disorder, post-traumatic stress disorder and hypersomnia. The same endpoint returns 11 on an exact product-name match, so even the count depends on how loosely the product name is matched.⁵

Those two numbers do not contradict each other. FDA's search ran through December 4, 2025. The public extract we queried was last updated on July 30, 2026, and BPC-157 drew heavy official attention in between, including the April 2026 compounding decision and the July advisory committee meeting. Attention drives reporting.

What the psychiatric entries support is narrow. Four single reports, each one person, with other peptides present in some cases, no denominator, and no causality assessment by anyone. A spontaneous report records that somebody told a regulator something happened. Spontaneous reporting is built to flag things for investigation, not to measure how often they occur. openFDA attaches its own warning: "Do not rely on openFDA to make decisions regarding medical care."⁵

So isolated psychiatric reports do sit in the FDA's system, and nobody has assessed them.

How common is it?

Nobody knows. Only one number has been published, and it is not a rate.

A preprint posted in September 2026 searched 15.2 million patients' clinical notes and found 1,536 whose notes mentioned BPC-157, of whom "1,039 (67.6%) had documented use." Among those 1,039 it reported "documented evidence of neuropsychiatric (1.4%)" effects.⁶

No other frequency figure has been published for this question. How much weight it can hold depends on where it came from.

• It is not peer reviewed. The page says so: "This version is not peer-reviewed."⁶
• The authors work for the company that ran it. The preprint's disclosure states its authors "are employees of nference, inc."⁶
• The category is not psychiatric. The paper defines it as "neurologic/psychiatric (e.g., mood change, anxiety, insomnia, headache)."⁶ Headache sits in the same bucket as anhedonia, so the 1.4% cannot be read as a mood figure.
• The authors say it is not incidence. In their own words: "Adverse-event findings are documented signals, not prospectively ascertained incidence."⁶

Individual symptoms are also suppressed. Any cell with a patient count below 11 is shown only as fewer than 11. Every separate symptom inside that 1.4% was too rare to print.⁶ Readers will find that percentage in the abstract and nowhere in the results.

A number that lumps headache with anhedonia, comes from notes rather than from asking anyone, is suppressed at the term level, and is disclaimed by its own authors, is a floor on what clinicians happened to write down. It is not an answer to how often this happens.

What does the animal research predict?

The opposite of what people report, in every test that measured mood.

Anyone describing their own flat mood has probably not been told this part, and it cuts both ways.

In 2000 the Zagreb group that produced nearly all of this literature ran BPC-157 through two standard rodent depression assays. In the forced swim test they recorded "a reduction of the immobility time in BPC 157 (10 microg, 10 ng x kg(-1) i.p.) treated rats."³ Less immobility is the direction antidepressants move the needle. In a chronic unpredictable stress protocol they reported the same reduction after four and six days.³ Its title calls the effect antidepressant.

Anxiety tests pointed the same way. A 2001 paper reported reduced burying in a shock-probe test and more movement in the dark zone of a light-dark box. Its authors read both as anxiolytic.⁷

Then there is the one study that measured anhedonia directly, and it needs care.

Does the anhedonia study show what its abstract claims?

A 2022 paper in Biomedicines gave ketamine to rats and ran the sucrose preference test, the standard way to measure anhedonia in a rodent. That paper's abstract states that "BPC 157 counteracted ketamine-cognition dysfunction, social withdrawal, and anhedonia" and that it "exerted additional anxiolytic effect."⁸

Its own discussion says something narrower. On the anhedonia test it reports that BPC 157 "counteracted L-NAME-effect only."⁸ That is not the same claim as the abstract's.

We are flagging this because the abstract is what gets quoted and the discussion is what was measured. On a question this thin, the discussion is the weaker-sounding and more reliable of the two, since an abstract summarizing more than its results section is a known failure and the reverse is not. The study also gives BPC-157's dose three different ways in three places, as 0.01 mg/kg, 10 ng/kg and 10 µg/kg, and two of those are a thousandfold apart.⁸ Six rats per group.⁸

So the single direct measurement of anhedonia is internally inconsistent. Nothing in it points toward BPC-157 causing anhedonia. It just supports less than its abstract claims.

Does BPC-157 lower serotonin in the brain?

One study is the source of every claim you will read about BPC-157 and serotonin. It says less than they do.

A 2004 paper measured the rate at which rat brain regions make serotonin. After a single dose it "significantly reduced the regional rate of 5-HT synthesis in the dorsal thalamus, hippocampus, lateral geniculate body and hypothalamus." In the same animals, synthesis rates "in the substantia nigra reticulate and medial anterior olfactory nucleus were significantly higher than in the control rats."⁹ After seven days of dosing, synthesis fell in the dorsal raphe nucleus and rose in the substantia nigra, lateral caudate, accumbens nucleus and superior olive.⁹

That is a region-by-region split, with some areas up and some down, in both dosing patterns. It is not a general lowering of serotonin.

It also measures synthesis rate. Not release, not turnover, not how much serotonin reaches a synapse, and not behavior. Reviews that describe BPC-157 as increasing serotonin release are describing something this study did not measure, and no study has.

Why this is worth your attention anyway. If you went looking for a reason BPC-157 might flatten mood, this is where you would stop: a drug that lowers serotonin synthesis in the hippocampus and the raphe sounds like a drug that could make someone feel worse. It is the strongest version of the argument and we would rather you read it here, in full, than find half of it somewhere else. It does not hold up, for three reasons. The same study found increases elsewhere. The behavioral tests ran in the same species at the same dose and went the other way. A synthesis rate in a rat brain region is also several steps removed from how a person feels.

Who ran that animal research, and has anyone repeated it?

One group. Nobody outside it has repeated the work.

Predrag Sikirić at the University of Zagreb is an author on every primary animal study of BPC-157 and the nervous system that we could locate, across nearly thirty years. So are a recurring set of the same colleagues. The reviews that summarize this work are largely written by the same group, so a reader counting papers is substantially counting one laboratory citing itself.

The nearest thing to an outside contribution is the serotonin synthesis study, whose first and corresponding authors were at the Montreal Neurological Institute and used a method developed there. Sikirić is a co-author on it, so it is a collaboration that produced a new result rather than an independent check on an old one.

We found no replication of any of this by an unconnected group. Reviews by teams in Warsaw, Gdansk and Silesia cite the Zagreb experiments without repeating them.

None of that makes the findings wrong. It does mean the animal evidence pointing away from mood harm rests on one laboratory. That is a thinner foundation than the paper count suggests. That absence is not evidence of safety. It mostly reflects that nobody has looked in people.

How long does BPC-157 stay in the body?

Minutes, on the only measurements that exist. That sits awkwardly with an effect lasting days.

Human pharmacokinetics for this compound come from a single study of two people, aged 58 and 68, given intravenous infusions. Serial blood sampling in those two showed "a half-life of under 30 min," with elimination through the kidneys.⁴ Another account of the same study reports that "plasma BPC-157 concentrations returned to baseline levels within 24 h."¹

Animal figures run shorter still. The Pharmaceutics review reports an elimination half-life of "15.2 min in rats and 5.27 min in beagle dogs" after intravenous dosing, drawn from a study we could not read ourselves.⁴ That review also notes the peptide breaks down into six small fragments and leaves through urine and bile.⁴

Two details in that record bear directly on mood.

Start with where the compound goes. In the animal distribution work, "brain and adipose tissue exhibited the lowest concentrations" of any tissue measured.⁴ A molecule that reaches the brain less than anywhere else is a difficult candidate for a direct central effect. Serotonin data pointed at the same conclusion from a different angle.

Then there is how little anchors any of this. The review states that "no comprehensive human pharmacokinetic studies have been conducted," that volume of distribution, plasma protein binding and oral bioavailability are uncharacterized in people, and that "no study to date has characterized the relationship between plasma BPC-157 concentrations and observed biological effects."⁴ Two subjects, one route, no absorption phase measured, and the method behind the numbers not fully reported.⁴

Short half-life does not settle it, and the page should not pretend otherwise. A drug can be gone from plasma in half an hour and still set off something that outlasts it. An immune response works that way. So does any effect that runs through a change the body then has to undo. What the timing does rule out is the simplest story, in which the molecule is sitting in your brain while you feel flat. On these numbers it is not there, in either sense.

Could something you took with it explain this?

Two of the three FDA reports could not be interpreted for exactly this reason. The same problem lands in a consultation room.

BPC-157 is frequently taken alongside other compounds. The FDA's own case summaries show it: one report involved someone "also using injectable compounded thymosin," and another concerned "the product containing BPC-157 and TB500."² On that second report the reviewers wrote that "because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs."²

The pattern repeats in the clinical record. In the chart review of knee pain, "four patients also received a combination of BPC-157 with TB4," a fragment of a different protein.¹

So in the small body of documented human exposure, co-administration is common enough that the agency reviewing it could attribute almost nothing. Neither we nor anyone else can tell you how often people combine compounds, because nobody has counted. What can be said is that a second substance makes a mood change uninterpretable, and that of everything on this page, it is the most likely to be true of any given account.

Our guide on mixing peptides covers what combining compounds does to the question of which one caused what.

Could the vial explain it instead?

It has more behind it than the drug does. FDA raised it independently.

Everything sold as BPC-157 today is unapproved, and the FDA's July 2026 review treated what is in the vial as a live safety question rather than a side issue. FDA reviewers wrote that "the nominators did not provide, and we did not identify any studies that formally investigated the immunogenicity of BPC-157 products."² On route, they wrote that "as a peptide with 15 amino acids that is administered through a parenteral or nasal ROA, BPC-157 may pose a significant risk for immunogenicity, potentially amplified by aggregation."²

The committee's recommendation followed from that. The briefing document states that "the evaluation criteria weigh against placing both BPC-157 (free base) and BPC-157 acetate on the list of bulk drug substances that can be used to compound drug products in accordance with section 503A."²

An immune response to an injected peptide or to what it is dissolved in produces fatigue, aches and feeling generally unwell. Those sit a long way from a mood disorder, and close to how some accounts of this read. Our guide on reading a certificate of analysis covers what a test on a vial does and does not establish, and our page on what purity figures mean explains why a high number on a certificate says nothing about the rest of the vial's contents.

The authors of the journal paper that carried the symptom list reached for the same explanation, pointing at "the unregulated production and variable dosing of BPC-157, amongst other causes."¹

So the product is a real candidate, and it is untestable after the fact without a sample of the specific vial.

What about people who report the opposite, or nothing at all?

They exist. Leaving them out would make this look sharper than it is.

Accounts of BPC-157 include people reporting better sleep and steadier mood, and far more people reporting nothing about mood in either direction. Only one kind of account tends to get written down and shared, because feeling fine is not something people post about. That is a known distortion in any collection of self-reports, and it runs in both directions here: it inflates the dramatic reports and it hides the quiet ones.

This is why the frequency question cannot be answered from reports at all, however many you read. A pile of accounts has no denominator. You cannot divide by the number of people who took it and felt normal, because nobody counted them.

Which of these explanations actually fits?

None of them is established. They are not equally supported, though, and the differences are checkable.

Explanation	What supports it	What is against it	What would test it
The peptide itself	Reports name the compound, and four single FAERS entries exist for anxiety, depression, OCD and PTSD5	No human study has looked; every animal mood test went the opposite way; plasma clearance is under 30 minutes and brain levels are the lowest of any tissue34	A controlled trial with a mood scale applied to both arms
What is in the vial	FDA found no immunogenicity studies and flagged significant risk for injected use; everything sold is unapproved and uncharacterized2	No test result has been published for any vial someone reacted to	A laboratory test on a sample from a specific vial
Something taken alongside it	Two of the FDA's three reports were uninterpretable because a second peptide was present; four of twelve knee-pain patients also received TB412	Nobody has counted how often compounds are combined, so no rate exists	A record of everything taken, in the same timeframe
Something unrelated	Low mood, poor sleep and loss of interest are common and have many causes, none of which stop happening because someone started a peptide	Timing that tracks a dose would argue against it in an individual case	A clinician working through the ordinary causes first

The second and third rows are the ones carrying the most weight, and both point away from the molecule. That is not the same as clearing it. What it means is that the two explanations with real evidence behind them are the two that have nothing to do with what BPC-157 does in the body.

What would actually settle this?

A trial that measured mood would settle it. So would a tested vial. Neither exists.

This question has an answerable form. Give a known quantity of a characterized compound to a counted group of people, give a matched group a placebo, and ask both groups about mood on a validated instrument. That design is ordinary. No such trial has ever been run on BPC-157 for any outcome, let alone this one, and the one trial that could have described what the compound does in healthy people was terminated without reporting.⁴

What would move this from an open question to a finding is missing on every count.

• A mood measure in a controlled trial. Not an adverse event tally, since that records only what someone thought to mention, but a scale applied to everyone in both arms.
• A tested sample from a vial someone reacted to. Without it, the drug and the product cannot be separated, and the FDA's immunogenicity concern cannot be checked against a real case.
• A denominator. Any frequency claim needs the number of people who took it and felt normal, and no collection of reports contains that number.

Until then the accurate statement is narrow. People report these effects, no study has looked for them, the animal work predicts the opposite, the compound leaves plasma in under half an hour and reaches the brain less than any other tissue, and what is in the vial is unverified.

When should you stop and be seen?

Some of what gets described in these accounts is not a side effect question.

Low mood that persists, loss of interest in things you normally enjoy, sleep that will not come back, or any thought of harming yourself are reasons to talk to a doctor regardless of what you have been taking. These are treatable, and they deserve proper attention, not filing as a reaction to a vial. If you are having thoughts of harming yourself, the 988 Suicide and Crisis Lifeline is available in the US by call or text at 988.

Two practical points apply if you are trying to work out whether something you took is involved.

A clinician can only help with what you tell them, and that includes the compound, how you took it, and anything else you were taking at the same time. Two of the three adverse event reports the FDA reviewed were uninterpretable precisely because a second peptide was involved.² Clinicians hit the same wall.

Timing is also information. Whether something started within hours of a dose, built over weeks, or was already there beforehand is the kind of detail that no database holds and that only you can supply.

Common questions

Can BPC-157 cause anxiety or depression?

How common are mood side effects on BPC-157?

Is anhedonia a known side effect of BPC-157?

Does BPC-157 affect serotonin?

Does the animal research say BPC-157 causes depression?

Why do the reports and the research disagree?

Has the FDA found psychiatric side effects of BPC-157?

Can BPC-157 cause insomnia?

Does BPC-157 cross the blood-brain barrier?

How long would it take for BPC-157 to leave my system?

Is BPC-157 approved or legal to compound?

Could it be the vial rather than the peptide?

Should I stop taking it?

What is BPC-157 actually proven to do in people?

Sources

1. Yuan C, Demers A, Silva-Ortiz V, Hasoon JJ, Lee W, Dave K, Amirdelfan K, Burke HW, Christo PJ, Robinson CL. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. Int J Mol Sci 2026;27(6):2876. doi:10.3390/ijms27062876. mdpi.com. Read at source, published 22 March 2026 as a Perspective. The symptom passage reads: "Very limited safety information is available for BPC-157 therapy in humans," and "anecdotal evidence from the use of BPC-157 has raised concerns." "Anonymous online user narratives reported injection site swelling and pain, anxiety, heart palpitations, weakness, depression, loss of appetite, fatigue, insomnia, joint pain, drowsiness, and anhedonia." Caveats, verbatim: "It is important to recognize that these data are unconfirmed and ought to be treated cautiously, placed low in the evidence hierarchy," and it is "worth considering how these complaints may manifest due to the unregulated production and variable dosing of BPC-157, amongst other causes." The passage cites the paper's reference 25; the reference list in the readable page text ends at entry 12, so reference 25 could not be identified. Human study sizes given as n=12 (knee pain chart review), n=12 (interstitial cystitis pilot) and n=2 (intravenous safety), plus an unpublished 2015 Phase 1 trial of 42 patients. Added after the first draft, because the page now uses them: on the two-subject intravenous study, "plasma BPC-157 concentrations returned to baseline levels within 24 h"; and on the knee-pain chart review, "four patients also received a combination of BPC-157 with TB4, a naturally occurring protein fragment", of whom "via survey, three reported significant improvement, while one had no pain relief". This paper does not name TB-500 and gives no figure for how often BPC-157 is combined with anything. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9
2. FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate). Briefing document, Pharmacy Compounding Advisory Committee meeting July 23-24, 2026; memo dated 5/11/2026. US Food and Drug Administration. fda.gov. Read at source; Section III, the formal conclusion and recommendation, was truncated in the retrieved text and is not quoted here. FAERS section: "The Office of Surveillance and Epidemiology conducted a search of the FAERS database for reports of adverse events (AEs) for BPC-157 through December 4, 2025." "The search retrieved three reports." "All reports were associated with injectable BPC-157." Case details: "She reported 9 days of redness and swelling around the injection site; however, she was also using injectable compounded thymosin"; "The patient developed shortness of breath, which resulted in an emergency room visit"; "The patient developed diffuse hyperpigmentation and gingival darkening following initial use of the product containing BPC-157 and TB500 for one week," with "The AEs were likely due to the drug product considering that the AEs occurred upon rechallenge; however, because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs." Safety conclusion: "There is insufficient clinical safety information to characterize the safety profile of BPC-157 (free base) and BPC-157 acetate." Immunogenicity: "The nominators did not provide, and we did not identify any studies that formally investigated the immunogenicity of BPC-157 products"; "In general, SC and nasal ROA is associated with increased immunogenicity compared to oral or rectal ROA"; "As a peptide with 15 amino acids that is administered through a parenteral or nasal ROA, BPC-157 may pose a significant risk for immunogenicity, potentially amplified by aggregation." Recommendation, from the introduction: "For the reasons discussed below, we believe the evaluation criteria weigh against placing both BPC-157 (free base) and BPC-157 acetate on the list of bulk drug substances that can be used to compound drug products in accordance with section 503A." On the Phase 1 trial: estimated enrollment of 42 subjects and "There are no results posted." ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15
3. Sikirić P, Šeparović J, Buljat G, Anić T, Stančić-Rokotov D, Mikuš D, Marović A, Prkačin I, Duplančić B, Zoričić I, Aralica G, Lovrić-Benčić M, Žiger T, Perović D, Rotkvić I, Miše S, Hanževački M, Hahn V, Seiwerth S, Turković B, Grabarević Ž, Petek M, Ručman R. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats. A comparison with antidepressants. J Physiol Paris 2000;94(2):99-104. doi:10.1016/S0928-4257(00)00148-0. PMID 10791689. Read via a reproduction of the published abstract on the Croatian Scientific Bibliography; the Elsevier full text is robots-disallowed, so the methods, group sizes and statistics could not be read. Verbatim from the abstract: "In a forced swimming test, a reduction of the immobility time in BPC 157 (10 microg, 10 ng x kg(-1) i.p.) treated rats"; "a reduction of the immobility of chronically stressed rats was noted after both 4 and 6 d of BPC 157 (10 microg, 10 ng) medication." Rats, intraperitoneal dosing. No group size is stated in the readable source. ↩1 ↩2 ↩3 ↩4
4. Mateescu D-M, Gavrilescu D-M, Constantinescu FE, Oancea C, Ilie A-C, Folescu R, Popa M-D, Iurciuc S, Muresan C-O, Enache A. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics 2026;18(5):625. doi:10.3390/pharmaceutics18050625. mdpi.com. Read at source, published 20 May 2026 as a Review; the final 7,981 characters of the page were not retrieved. Verbatim: "No human CNS data exist for BPC-157 in any neurological indication." On the human record: "Available clinical data derive from fewer than 30 subjects across three uncontrolled pilot studies." On the Phase 1 trial, that it "was terminated without publication of results." Pharmacokinetics, added after the first draft because the page now uses them: the review states that "the only available human pharmacokinetic data derive from a two-subject pilot study by Lee and Burgess", in which "serial plasma sampling demonstrated a half-life of under 30 min" with primary renal clearance, and that "a sample size of two subjects is statistically insufficient to characterize inter-individual pharmacokinetic variability", that "intravenous administration does not characterize the absorption phase", and that "the bioanalytical methodology was not fully reported, precluding independent assessment of data quality". Animal figures, which the review draws from a primary study by He et al. that could not be read for this page: "the elimination half-life (t1/2) of BPC-157 was 15.2 min in rats and 5.27 min in beagle dogs"; "absolute intramuscular bioavailability was 14-19% in rats and 45-51% in beagle dogs"; "rapid proteolytic hydrolysis to six identified small peptide fragments (M1-M6)" with "primary excretion routes were urinary and biliary"; and on distribution, "brain and adipose tissue exhibited the lowest concentrations". On the gaps: "no comprehensive human pharmacokinetic studies have been conducted"; "volume of distribution, plasma protein binding, oral bioavailability" are uncharacterized in humans; and "no study to date has characterized the relationship between plasma BPC-157 concentrations and observed biological effects". The review also states the He et al. study "was not conducted under full Good Laboratory Practice (GLP) conditions". The figures in this annotation were read at the same source on a second pass, from character offset 30,000 onward. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11
5. openFDA drug adverse event endpoint, queried October 19, 2026. api.fda.gov. Queried on the field patient.drug.medicinalproduct, tokenized rather than exact, which returns 18 reports. The same query against patient.drug.medicinalproduct.exact returns 11 against the same extract, so the field is recorded here because the count does not reproduce without it; the tokenized form is the broader of the two because it also matches the spacing variants of the name. Response metadata gives a last-updated date of 2026-07-30 for the public FAERS extract. A known-positive control was run on the same field in the same session and returned a plausible total, so the endpoint was behaving. A separate count query on reaction terms returned 100 distinct terms whose counts sum to 114, including ANXIETY 1, DEPRESSION 1, OBSESSIVE-COMPULSIVE DISORDER 1, POST-TRAUMATIC STRESS DISORDER 1, HYPERSOMNIA 1 and SERUM SEROTONIN INCREASED 1. That term list is capped at 100 entries and ran alphabetically only as far as VISION BLURRED, so terms after that point may be missing; a higher-limit re-query was refused. An earlier query during research returned 15 on an unrecorded field, which is why this footnote names the field. The endpoint's own disclaimer: "Do not rely on openFDA to make decisions regarding medical care." ↩1 ↩2 ↩3
6. Venkatakrishnan AJ, Marwaha A, Gregg CJ, Varma G, Hurchik M, Murugadoss K, Shivabasappa S, Soundararajan V. Rising Use of Unapproved BPC-157 ("Wolverine Peptide") and Associated Patient-Reported Outcomes Curated from Clinical Notes. Preprints.org, posted 7 September 2026. doi:10.20944/preprints202609.0501.v1. preprints.org. Read at source; the final 4,365 characters of the page were not retrieved. The page states "This version is not peer-reviewed." Conflict of interest, verbatim: "The authors are employees of nference, inc., which conducts research collaborations with various biopharmaceutical companies whose therapeutic products are included in this study." Denominator, verbatim: "Of 1,536 patients with a note mentioning BPC-157, 1,039 (67.6%) had documented use." The figure, verbatim and appearing in the abstract only: "documented evidence of neuropsychiatric (1.4%)". Category definition from the Figure 3 caption: "neurologic/psychiatric (e.g., mood change, anxiety, insomnia, headache)". Suppression rule from Methods 2.6: "Any cell with a patient count below 11 is reported as" "<11". Authors' disclaimer from the Figure 3 caption: "Adverse-event findings are documented signals, not prospectively ascertained incidence." Method: retrospective analysis of de-identified clinical notes from a federated network of 15.2 million patients. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6
7. Sikirić P, Jelovac N, Jelovac-Gjeldum A, et al. Anxiolytic effect of BPC-157, a gastric pentadecapeptide: shock probe/burying test and light/dark test. Acta Pharmacol Sin 2001;22(3):225-230. PMID 11742568. Read via a reproduction of the published abstract on the Croatian Scientific Bibliography; no DOI exists for this paper and the full text could not be read. The journal, year, volume, issue, pages and PMID were verified independently against the OpenAlex metadata registry, which renders one of the eighteen author names inconsistently with the companion papers, so the list is abbreviated here instead of printed in full. The abstract describes reduced burying in the shock-probe test and increased dark-area activity in the light/dark test, at 10 micrograms and 10 nanograms per kilogram intraperitoneally, compared against diazepam. The abstract describes the shock-probe arm in rats and the light/dark arm in mice, which is an inconsistency in the source itself. No group size is stated in the readable source. ↩1
8. Zemba Čilić A, Zemba M, Čilić M, Štrbe S, Ilić S, Vukojević J, Zoričić Z, Filipčić I, Kokot A, et al., Sikirić P. BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling "Negative-Like" Symptoms of Schizophrenia. Biomedicines 2022;10(7):1462. doi:10.3390/biomedicines10071462. mdpi.com. Read at source, published 21 June 2022; the author list is truncated on the page and should be completed from the DOI. Male Wistar rats, "6 rats per group", intraperitoneal dosing: "Medication (mg/kg intraperitoneally) was L-NAME (5), L-arginine (100), and BPC 157 (0.01)." Tests included novel object recognition, social interaction, open field and sucrose preference. The abstract states "BPC 157 counteracted ketamine-cognition dysfunction, social withdrawal, and anhedonia" and that it "exerted additional anxiolytic effect." The discussion states that on the anhedonia test BPC 157 "counteracted L-NAME-effect only," which is a narrower claim than the abstract's; this page reports both and treats the discussion as the more reliable. The paper also states the BPC 157 dose three ways in three places, as 0.01 mg/kg, 10 ng/kg and 10 µg/kg. ↩1 ↩2 ↩3 ↩4
9. Tohyama Y, Sikirić P, Diksic M. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyl-L-tryptophan autoradiographic measurements. Life Sci 2004;76(3):345-357. doi:10.1016/j.lfs.2004.08.010. PMID 15531385. Read via a reproduction of the published abstract on the Croatian Scientific Bibliography; the Elsevier full text is robots-disallowed. First and corresponding authors were at the Montreal Neurological Institute and Hospital, McGill University; Sikirić is a middle author. Acute arm, a single 10 micrograms per kilogram intraperitoneal dose given 40 minutes before measurement: "significantly reduced the regional rate of 5-HT synthesis in the dorsal thalamus, hippocampus, lateral geniculate body and hypothalamus," while "5-HT synthesis rates in the substantia nigra reticulate and medial anterior olfactory nucleus were significantly higher than in the control rats," and "No significant change in the synthesis rate was observed in the raphe nuclei." Chronic arm, seven days at 10 micrograms per kilogram subcutaneously: "a significant reduction in the 5-HT synthesis rate was observed in the dorsal raphe nucleus," with "significant increases" in "the substantia nigra, lateral caudate, accumbens nucleus and superior olive." The measurement is of synthesis rate, not release or turnover. No group size is stated in the readable source. ↩1 ↩2

Sources that could not be read for this page

• The three Reddit threads supplied with this brief, in r/bpc_157. Reddit is blocked to the tools used for this page and was not read through any cache or mirror. No thread content is asserted anywhere above, and the brief's count of six threads is not repeated because only three links were supplied and none was opened.
• PubMed and PubMed Central, for every paper cited here. Both serve a reCAPTCHA check. Citations were verified against publisher pages, the OpenAlex metadata registry and the Croatian Scientific Bibliography instead.
• ScienceDirect and Elsevier full texts, for the 2000 depression paper and the 2004 serotonin paper, both robots-disallowed. Only the published abstracts were read, which is why no group sizes or statistics appear for either.
• ClinicalTrials.gov, robots-disallowed, so no trial record was read directly and no NCT number is quoted from the registry.
• Full texts of the three human pilot studies, all subscription-only in Alternative Therapies in Health and Medicine.
• Reference 25 of the 2026 perspective paper, the source of the symptom list, because the readable reference list ends at entry 12.
• Section III of the FDA briefing document, the formal conclusion and recommendation, truncated in the retrieved text. The recommendation quoted above comes from the document's introduction instead.